The VDJ001 project, a head product of Weidejie Biotechnology, was awarded the "Top 10 Engineering Practice Cases in the Capital of 2023" in the annual capital engineering innovation practice case collection activity organized by the Beijing Association for Science and Technology.

　　On April 12th, the "Beijing Engineering Science and Technology Talent Development Achievement Exhibition and Capital Innovation Engineering Practice Case Exhibition and Exchange Activity" was grandly held in Beijing. Leaders from departments such as the Beijing Association for Science and Technology and the Development Research Center of the State Council attended the event and delivered speeches. The Capital Innovation Engineering Practice Case Awards were held simultaneously at the conference, and the Beijing Association for Science and Technology commended the "Top Ten Cases" and 20 "Excellent Cases" that have achieved outstanding achievements in the practice of the Capital Innovation Engineering. These cases cover five major industries including electronic information, biomedicine, intelligent manufacturing, advanced materials, and green low-carbon.

　　As the only award-winning enterprise in the biopharmaceutical industry, Dr. Li Ziqiang, founder of Weidejie Biotechnology, presented a case study titled "Innovative IL6R Antibody Drugs in the Field of Autoimmune Diseases Based on Antibody Optimization Platform Simulating Human Antibody Maturity Mechanism" as a representative of the "Top Ten Cases" of Capital Innovation Engineering Practice at the conference. The leaders and guests on site fully affirmed the development of Weidejie Biotechnology in the field of innovative drugs. The capital side present highly recognized and appreciated the project, and expressed that it conforms to the hard technology investment direction of "hard threshold, hard efficacy, and hard talent".

　　Top Ten Cases of Capital Innovation Engineering Practice:

　　Innovative engineering practice cases are an important measure taken by the Beijing Association for Science and Technology to serve technological innovation. The aim is to discover and commend innovative projects that meet the major strategic needs of the country and Beijing, and are committed to high-quality development, to promote the exploration of new paths for engineering innovation in the capital, the construction of new scenarios, and the implementation and application of new technologies.

　　Regarding VDJ001:

　　The VDJ001 project is the first/only innovative inhibitor of IL-6R in China, with international patents authorized in multiple countries including China, the United States, South Korea, and Japan. In the phase II clinical trial of iMCD led by Peking Union Medical College, the effect was excellent, with fast onset of action and high percentage of tumor shrinkage in all subjects; In the Phase II clinical trial of RA indications for MTX resistance led by the People's Hospital, the clinical trial results of VDJ001 and tocilizumab head meeting showed that it has the best potential in its class. At present, these two indications are about to enter critical clinical research, with the potential for domestic substitution and surpassing imported products.

　　Regarding Weidejie:

　　Beijing VDJBio Co., LTD. is a national high-tech enterprise and a specialized and innovative small and medium-sized enterprise in Beijing. Focusing on the development of the best innovative antibody drugs in the field of autoimmune diseases. The company utilizes its unique antibody discovery and optimization platform, as well as a comprehensive small, medium, and industrial production platform for large molecule drugs, to develop a series of drugs with the best in class for the treatment of autoimmune diseases.